This page shows the latest Spirogen news and features for those working in and with pharma, biotech and healthcare.
AZ boosted its pipeline in thsi area with the $440m acquisition of Spirogen.
with a move away from commercial-led megamergers and a shift towards small- and mid-scale, science-led acquisitions such as its recent purchase of Spirogen.
Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.
AZ's 2013 deal-making spree also saw it acquire Amplimmune, a Maryland, US-based biotech with a number of early-stage cancer projects, and UK firm Spirogen, which develops ... Financial details of the AlphaCore deal were not released, but AZ's
Last month the company agreed to pay $440m to buy antibody-drug conjugate (ADC) specialist Spirogen, while in August it bought cancer company Amplimmune in a deal valued at up to
the economic downturn, as well as Biomoti, Mediwise, Duvas Technologies, Spirogen and The Specialist Pharmacy.
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Auven's portfolio of companies includes Resolvyx, Kiacta, Kolitan and Sprout Pharmaceuticals, as well as Spirogen and ADC Therapeutics. . ... The Spirogen/Auven Therapeutics deal with MedImmune discussed above re-confirms that ADC technology is
730. Spirogen / MedImmune. Acquisition. ADC technology - oncology (lead asset in phase II).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...